Search the Newsreel

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths

Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health …

Crinetics Pharmaceuticals (CRNX): Wellington reports 7.13M-share, 6.76% ownership

Wellington Management entities have reported beneficial ownership of 7,131,084 shares, or 6.76%, of Crinetics Pharmaceuticals (CRNX) common stock. The filing indicates shared voting power over 6,310,651 shares and shared dispositive power over all 7,131,084 shares, with economic interests belonging to advisory clients. No single …

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet …

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Crinetics Pharmaceuticals stock hits all-time high at 84.35 USD

Crinetics Pharmaceuticals (CRNX) stock reached an all-time high of $84.35, reflecting a 196.14% increase over the past year and a current market capitalization of approximately $8.94 billion. Despite its strong performance, InvestingPro data suggests the stock might be overbought and overvalued. The company recently …

Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing?

Neurocrine Biosciences (NBIX) has commenced a Phase 1 study for its obesity treatment candidate, NBIP 1968, following positive Q2 and H1 2026 financial results. Despite recent stock momentum and a current share price of $163.41, Simply Wall St's analysis suggests the company might be …

First Trust Advisors LP Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX

First Trust Advisors LP increased its stake in Crinetics Pharmaceuticals (CRNX) by 54.9% in the first quarter, now holding 51,365 shares valued at $1.87 million. Despite insider stock sales, the company reported strong Q1 earnings, beating revenue estimates by 2336.9% year-over-year. Analysts have a …

Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers significantly increased its stake in Neurocrine Biosciences (NBIX) by 50.1% in the first quarter, now owning 20,245 shares valued at $2.67 million. Institutional investors hold 92.59% of NBIX. Despite insider sales totaling over $62 million in the past quarter, analysts maintain …

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-08-07

This article announces that Neurocrine Biosciences, Inc. (NBIX) has published its slide deck in conjunction with its Q2 2026 earnings call. The earnings call presentation was made on August 7, 2026. The article was written by the Seeking Alpha Transcripts team, which regularly publishes …

Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC

PKO BP BANKOWY Universal Pension Society JSC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 23.1% in the second quarter, now holding 170,802 shares valued at $28.8 million. This move highlights continued institutional investor interest, with several other hedge funds also boosting their …

ETFs Investing in Neurocrine Biosciences, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Neurocrine Biosciences, Inc. The list, sorted by market value, provides details such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV …

How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors

Neurocrine Biosciences recently reported strong Q2 2026 results, with significant revenue and net income, alongside a new equity shelf registration tied to an ESOP offering. This dual development highlights the company's efforts to strengthen employee ownership and financial flexibility. The article discusses how these …

Crinetics Pharmaceuticals (NASDAQ: CRNX) sees 1.4% stake reported by FMR LLC

FMR LLC and Abigail P. Johnson have reported an amended passive investment disclosure for Crinetics Pharmaceuticals (CRNX) via a Schedule 13G/A filing. FMR LLC holds beneficial ownership of 1,439,890.88 shares, representing 1.4% of the common stock outstanding, with nearly all shares holding sole voting …

Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Glenmede Trust Co. NA

Glenmede Trust Co. NA increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 72.6% in the first quarter, now holding 29,245 shares valued at $1.06 million. Despite some insider selling, institutional investors own 98.51% of the company. Crinetics Pharmaceuticals reported better-than-expected Q1 earnings with a …

Accenture (ACN) Following UniCredit Deal And IBM Tie Up Has A Valuation Split

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Accenture (ACN) is back in focus after UniCredit announced a long term collaboration with Accenture and IBM that includes Accenture acquiring a majority stake in …

Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed stock information for Neurocrine Biosciences, Inc. (NBIX), including its current price, historical data, financial performance, analyst ratings, and company overview. It highlights key products like INGREZZA and several pipeline candidates for neurological and psychiatric disorders. The company's market …

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Vertex Pharmaceuticals (NASDAQ: VRTX) has dominated the market for cystic fibrosis (CF) medicines since it earned approval for its first drug in this niche in 2012. To this day, most of the company's revenue comes from its CF franchise. In the second quarter, Vertex …

Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-'1968 for Obesity

Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist, as a treatment for obesity. This move signifies the company's entry into the multi-agonist incretin therapeutics market, aiming to address limitations of current GLP-1-based treatments such as gastrointestinal …

Crinetics Pharmaceuticals (CRNX) Stock Looks Rich On Book Value But Reasonable On Deal Value

Crinetics Pharmaceuticals (CRNX) has experienced a significant stock price increase of 403.6% over three years, making its current valuation appear high on market multiples. While the agreed acquisition by Vertex Pharmaceuticals for US$10.0 billion helps justify the current price, the stock's Price-to-Book ratio of …

Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift

Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences (NBIX), made a bona fide gift of 2,409 shares of common stock effective August 4, 2026. This transaction was a charitable contribution, not a market sale, and no value was received for the shares. After this …

Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount

Neurocrine Biosciences (NBIX) is presented as a compelling value stock due to its strong valuation score, profitability, and growth prospects despite trading at a higher-than-average P/E. The company boasts excellent financial health, a debt-free balance sheet, and impressive historical and projected EPS and revenue …

Crinetics Pharmaceuticals (CRNX) Stock Lags As Revenue Builds And Losses Deepen

Crinetics Pharmaceuticals (CRNX) has shown significant revenue growth, with Q2 2026 revenue reaching US$25.1 million, largely due to scaling product sales like PALSONIFY. Despite this, the company's net losses have deepened, reporting a US$120.9 million quarterly loss and a US$501.6 million trailing 12-month loss. …

Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD

Crinetics Pharmaceuticals' stock has reached an all-time high of $84.01, driven by a 187.21% increase over the past year and a market capitalization of $8.85 billion. This surge in value comes as Vertex Pharmaceuticals announced an agreement to acquire Crinetics for approximately $10 billion, …